June 2018

New Product - Trelegy Ellipta

Fluticasone furoate/umeclidinium (bromide)/vilanterol (trifenatate) (Trelegy Ellipta) represent three classes of medications: a synthetic corticosteroid (an inhaled corticosteroid (ICS)), a long-acting muscarinic receptor antagonist (LAMA), and a selective, long-acting β₂-receptor agonist (LABA), respectively. Trelegy Ellipta is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who require treatment with LAMA + LABA + ICS. Trelegy Ellipta is not indicated for the initiation of therapy in COPD. Trelegy Ellipta is contraindicated in patients with severe milk protein allergy. Trelegy Ellipta is available as a moulded plastic device containing two foil blister strips (each foil strip contains 30 regularly distributed blisters), with one strip containing fluticasone furoate 100 microgram and the other strip containing umeclidinium (bromide) 62.5 microgram and vilanterol (trifenatate) 25 microgram.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au